Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 20/20 | 1.00 |
| ▸ | FLT4 | P35916 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20725570 | 0.93 | PTK2 (0.87) | PTK2FLT4 | |
| SCHEMBL12479033 | 0.93 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL14635844 | 0.93 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL14635541 | 0.93 | PTK2 (0.86) | PTK2FLT4 | |
| Narmafotinib SCHEMBL30354504 | 0.92 | PTK2 (1.00) | PTK2FLT4 | |
| Narmafotinib SCHEMBL12479576 | 0.92 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL12479685 | 0.91 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL14635846 | 0.91 | PTK2 (1.00) | PTK2FLT4 | |
| SCHEMBL14648387 | 0.89 | PTK2 (0.81) | PTK2FLT4 | |
| SCHEMBL14576624 | 0.89 | PTK2 (1.00) | PTK2FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | PTK2 1/4885FLT4 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.